Akari Tests Dual-Payload ADC Strategy With WhiteHawk Collaboration
TAMPA, FL – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is pairing its proprietary PH1 spliceosome-modulating payload with WhiteHawk Therapeutics' TOP1 inhibitor antibody drug conjugate (ADC) platform to test a dual-payload approach in oncology. President and CEO Abizer Gaslightwala laid out the rationale in a new CEO Corner segment released today. The release does not disclose financial terms.
Akari combines two payload mechanisms in one research program
The strategic research collaboration joins PH1, which targets RNA splicing, with WhiteHawk's TOP1 inhibitor technology. Gaslightwala said the ADC field is moving beyond single-payload development toward combinations of complementary mechanisms. Akari expects the pairing to broaden therapeutic activity and to demonstrate the applicability of PH1 across multiple uses.